Introduction {#s1}
============

Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled and does not meet the recommended blood pressure (BP) goals \[[@R01]\]. New hypertension guidelines from the United States and Europe state that the recommended BP target in adults requiring drug treatment was changed from 140/90 to 130/80 mm Hg in those \< 65 years of age \[[@R02], [@R03]\]. Thus, the availability of antihypertensive drugs that will substantially reduce BP is likely to promote improved BP control rates.

Azilsartan, a long-acting angiotensin II receptor blocker (ARB), reportedly has greater antihypertensive effects than other ARBs \[[@R04]-[@R06]\]. In one study, azilsartan at 80 mg had superior efficacy to both valsartan at 320 mg and olmesartan at 40 mg, and azilsartan at 40 mg was noninferior to olmesartan at 40 mg \[[@R05]\]. Several studies have shown that azilsartan has pleiotropic effects such as improvement in cardiometabolic parameters \[[@R07]-[@R10]\]. Thus, azilsartan is a promising ARB for primary and secondary prevention of cardiovascular disease.

While many drug classes are available to reduce BP, the use of ARBs has become a popular strategy in the management of hypertension. In addition, in patients with uncontrolled hypertension using three or more antihypertensive drugs, the strong BP-lowering effect of each drug could provide higher rates of hypertension control. According to previous studies of azilsartan \[[@R04]-[@R06]\] and a fixed-dose tablet of an ARB and a calcium channel blocker (CCB) or an ARB and a diuretic at the usual dose in Japan \[[@R11]-[@R14]\], we hypothesized that azilsartan at 40 mg is more efficacious than these combination therapies. The purpose of this study was to evaluate the effect of azilsartan at 40 mg after switching from a fixed-dose combination tablet of an ARB at the usual dose in Japan and a CCB or hydrochlorothiazide (HCT) on BP.

Materials and Methods {#s2}
=====================

Ethical considerations {#s2a}
----------------------

The study was approved by the ethics committees of all participating hospitals and clinics. All participants provided written informed consent before enrollment. This study was conducted according to the principles expressed in the Declaration of Helsinki. The study is registered in the UMIN Clinical Trials Registry (UMIN000012587).

Patient population {#s2b}
------------------

Participants were enrolled at 11 affiliated hospitals or clinics of Okayama University in Japan from July 2012 to June 2014. Eligible patients were adults (\> 30 to \< 85 years old) who were undergoing treatment with a combination tablet including the usual dose of an ARB (excluding azilsartan) and the usual dose of a CCB or diuretic. Patients with the following conditions were excluded: secondary hypertension, grade III hypertension according to the Japanese Society of Hypertension 2009 guideline \[[@R15]\], congestive heart failure, severe valvular heart disease, myocardial infarction or cerebellar infarction within 6 months, chronic atrial fibrillation, malignant arrhythmia, renal insufficiency (serum creatinine concentration of ≥ 2 mg/dL), severe liver disease, chronic inflammatory disease, malignant disease (lifetime prognosis of \< 6 months), and treatment with a renin-angiotensin system inhibitor other than an ARB.

Study protocol {#s2c}
--------------

This study was a 24-week, prospective, multicenter open-label study with a single treatment arm ([Fig. 1](#F1){ref-type="fig"}). Before enrollment, eligible patients received a fixed-dose tablet of an ARB and amlodipine at 5 mg or azelnidipine at 16 mg (ARB/CCB) or a fixed-dose tablet of an ARB and HCT at 6.25 or 12.5 mg (ARB/HCT) in which azilsartan was not the ARB. The baseline ARB/CCB and ARB/HCT treatments are shown in [Table 1](#T1){ref-type="table"}. At the time of enrollment, the fixed-dose tablet was switched to azilsartan at 40 mg. After 12 weeks, addition of amlodipine at 5 mg was permitted according to the physician's decision if BP control was poor after switching to azilsartan. Treatment was continued for 24 weeks. Other drugs that could potentially interfere with the efficacy of the study medications were not allowed. All patients were reviewed for general health and compliance with medication, which was assessed by tablet counts and BP checks at each clinic visit.

![Study protocol. ARB/CCB: angiotensin II receptor blocker and amlodipine 5 mg or azelnidipine 16 mg; AEB/HCT: angiotensin II receptor blocker and hydrochlorothiazide 6.25 mg or 12.5 mg; BP: blood pressure.](jocmr-11-202-g001){#F1}

###### Patients' Characteristics

  --------------------------------------------------- ------------
  Age (years)                                         77 ± 6
  Male sex                                            18 (45)
  Body mass index, kg/m^2^                            23.7 ± 3.7
  Diabetes mellitus                                   5 (13)
  Dyslipidemia                                        20 (50)
  Chronic kidney disease                              5 (18)
  History of coronary artery disease                  9 (23)
  History of cerebrovascular disease                  2 (7)
  Current smoker                                      2 (7)
  Baseline antihypertensive drug                      
    ARB and calcium channel blocker                   25 (63)
      Valsartan 80 mg/amlodipine 5 mg                 9 (23)
      Olmesartan 20 mg/azelnidipine 16 mg             8 (20)
      Candesartan 8 mg/amlodipine 5 mg                6 (15)
      Irbesartan 100 mg/amlodipine 5 mg               1 (3)
      Telmisartan 40 mg/amlodipine 5 mg               1 (3)
    ARB and diuretic                                  15 (38)
      Valsartan 80 mg/hydrochlorothiazide 6.25 mg     8 (20)
      Telmisartan 40 mg/hydrochlorothiazide 6.25 mg   4 (10)
      Candesartan 8 mg/hydrochlorothiazide 6.25 mg    2 (5)
      Losartan 50 mg/hydrochlorothiazide 12.5 mg      1 (3)
  --------------------------------------------------- ------------

Data are presented as mean ± standard deviation or n (%). ARB: angiotensin II receptor blocker.

The primary outcome was the change in clinic BP after treatment with azilsartan at 40 mg for 24 weeks.

Measurement of in-clinic and home BPs {#s2d}
-------------------------------------

In-clinic BP and heart rate were measured in a sitting position three times at 1-min intervals using a validated oscillometric device after an initial 5 min of seated rest \[[@R16]\]. Home BP and heart rate were measured in a sitting position three times each morning and three times each evening for 5 consecutive days before the clinic visit (total of three visits) using a validated oscillometric device. The mean BP for 5 consecutive days was determined as the home BP. The patients were instructed to rest for 5 min before the first reading and rest for a 15-s interval between readings. Morning BP was measured within 1 h after waking, after urination, and before breakfast according to the Japanese home BP guidelines \[[@R17]\].

Blood sampling {#s2e}
--------------

Blood samples were collected from an antecubital vein after a 12-h overnight fast and after a rest of at least 30 min with the patient in the supine position. Routine biochemical parameters, including glycated hemoglobin and the serum concentrations of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, creatine, and uric acid, were measured immediately using an autoanalyzer.

Sample size {#s2f}
-----------

We hypothesized that the in-clinic systolic BP would be lower at 24 weeks than at baseline. We assumed a mean difference in the in-clinic systolic BP of 5 mm Hg, with a standard deviation of 12 mm Hg. Using a two-sided paired test for differences, a minimum sample size of 58 patients was required to detect statistically significant differences in systolic BP with a power of 80% and an α-type error of 5%.

Statistical analysis {#s2g}
--------------------

Continuous variables are presented as mean ± standard deviation, and categorical variables are presented as absolute value and proportion (%). Comparisons between two groups were performed by a paired *t*-test. Variables at baseline, 12 weeks, and 24 weeks were compared using one-way repeated analysis of variance followed by the Bonferroni post hoc analysis. A P value of \< 0.05 was considered statistically significant. Statistical analyses were performed using SPSS 24.0 for Windows (IBM Corp., Armonk, NY, USA).

Results {#s3}
=======

Characteristics of the study participants {#s3a}
-----------------------------------------

In total, 47 patients were enrolled in this study. Of these patients, 40 completed the study (seven patients were lost to follow-up). The baseline characteristics of these 40 patients are shown in [Table 1](#T1){ref-type="table"}. Their mean age was 77 years, and 45% were men. The proportion of patients with diabetes mellitus and dyslipidemia were 13% and 50%, respectively. The baseline fixed-dose combination tablet was an ARB/CCB in 63% of patients and an ARB/HCT in 38%.

Change in BP after switching to azilsartan {#s3b}
------------------------------------------

In all patients, the in-clinic and home BPs did not change significantly between baseline and follow-up ([Table 2](#T2){ref-type="table"}). A total of 33 patients (84%) completed this study without adding amlodipine after switching to azilsartan ([Fig. 2](#F2){ref-type="fig"}). Their in-clinic and home BPs did not change during the study period. However, in seven patients (16%), systolic BP was elevated at 12 weeks and amlodipine at 5 mg was therefore added ([Table 2](#T2){ref-type="table"}). The patients' baseline combination drugs were candesartan at 8 mg/amlodipine at 5 mg (n = 3), olmesartan at 20 mg/azelnidipine at 16 mg (n = 2), telmisartan at 40 mg/amlodipine at 5 mg (n = 1), and telmisartan at 40 mg/HCT at 6.25 mg (n = 1). Thus, among the seven patients whose BP was increased at 12 weeks, six patients had taken an ARB/CCB at baseline. The elevated systolic BP at 12 weeks significantly decreased after adding amlodipine at 5 mg ([Table 2](#T2){ref-type="table"}).

###### Change in Blood Pressure

                                       Baseline   12 weeks     24 weeks   P value^a^   P value^b^   P value^b^   P value^b^
  ------------------------------------ ---------- ------------ ---------- ------------ ------------ ------------ ------------
  All (n = 40)                                                                                                   
    Office SBP                         136 ± 13   137 ± 17     135 ± 14   0.567        1.000        1.000        0.731
    Office DBP                         74 ± 9     73 ± 8       74 ± 8     0.921        1.000        1.000        1.000
    Office HR                          69 ± 13    71 ± 12      70 ± 12    0.329        0.552        1.000        0.731
    Home SBP                           133 ± 14   136 ± 14     135 ± 11   0.407        0.724        0.873        1.000
    Home DBP                           71 ± 9     73 ± 8       74 ± 9     0.066        0.339        0.109        1.000
    Home HR                            69 ± 12    68 ± 10      67 ± 11    0.109        0.743        0.220        0.655
  Without addition of a CCB (n = 33)                                                                             
    Office SBP                         137 ± 12   135 ± 17     134 ± 14   0.715        1.000        1.000        1.000
    Office DBP                         74 ± 8     72 ± 8       72 ± 6     0.182        0.956        0.164        1.000
    Office HR                          67 ± 12    69 ± 11      67 ± 11    0.274        0.572        1.000        0.511
    Home SBP                           132 ± 12   134 ± 13     136 ± 12   0.246        1.000        0.433        0.880
    Home DBP                           71 ± 8     72 ± 7       74 ± 8     0.054        0.947        0.094        0.370
    Home HR                            68 ± 12    66 ± 10      65 ± 11    0.101        0.817        0.218        0.817
  With addition of a CCB (n = 7)                                                                                 
    Office SBP                         135 ± 20   150 ± 11\*   134 ± 10   0.270        0.180        1.000        0.012
    Office DBP                         73 ± 11    77 ± 8       82 ± 10    0.072        0.821        0.178        0.166
    Office HR                          79 ± 15    80 ± 11      81 ± 9     0.906        1.000        1.000        1.000
    Home SBP                           135 ± 20   141 ± 17     132 ± 10   0.338        1.000        1.000        0.616
    Home DBP                           74 ± 12    78 ± 12      75 ± 11    0.373        0.621        1.000        0.942
    Home HR                            75 ± 7     75 ± 8       73 ± 9     0.950        1.000        1.000        1.000

Data are presented as mean ± standard deviation. SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; CCB, calcium channel blocker. ^a^P value by one-way repeated analysis of variance. ^b^P value by the Bonferroni post hoc analysis. \*P \< 0.05 vs. at 24 weeks.

![Proportion of patients for whom amlodipine at 5 mg was and was not added at 12 weeks.](jocmr-11-202-g002){#F2}

The changes in the patients' biochemical parameters are shown in [Table 3](#T3){ref-type="table"}. The serum potassium level significantly increased after switching to azilsartan for 24 weeks, while the other parameters did not change.

###### Change in Biochemical Parameters

                             Baseline      6 months         P value
  -------------------------- ------------- ---------------- ---------
  Na (mEq/L)                 140.2 ± 1.7   140.0 ± 2.9      0.429
  K (mEq/L)                  4.2 ± 0.4     4.4 ± 0.5        0.013
  Cl (mEq/L)                 103.3 ± 5.8   103.2 ± 2.9      0.367
  BUN (mg/dL)                20.2 ± 6.1    19.5 ± 6.9       0.847
  Serum creatinine (mg/dL)   0.87 ± 0.20   0.98 ± 0.34      0.115
  Hemoglobin A1c (%)         5.9 ± 0.6     5.8 ± 0.7        0.167
  Triglyceride (mg/dL)       96.7 ± 41.9   112\. 2 ± 30.6   0.916
  LDL-cholesterol (mg/dL)    98.3 ± 36.9   94.5 ± 24.6      0.572
  HDL-cholesterol (mg/dL)    62.9 ± 13.6   56.8 ± 12.7      0.086
  Uric acid (mg/dL)          5.4 ± 1.3     5.8 ± 1.8        0.630

Data are presented as mean ± standard deviation. Na: sodium; K: potassium; Cl: chloride; BUN: blood urea nitrogen; LDL: low-density lipoprotein; HDL: high-density lipoprotein.

Discussion {#s4}
==========

This study demonstrated that switching to azilsartan at 40 mg from a fixed-dose combination tablet of an ARB/CCB or an ARB/HCT did not decrease the in-clinic or home BP. After switching to azilsartan at 40 mg, an increase in BP was observed in 16% of patients at 12 weeks. Our findings suggest that azilsartan at 40 mg has substantial efficacy in lowering BP, similar to a fixed-dose combination tablet of an ARB/CCB or an ARB/HCT.

Several studies have revealed the BP-lowering efficacy of azilsartan. Rakugi et al \[[@R04]\] reported that treatment with azilsartan at 20 to 40 mg reduced systolic BP by 21.8 mm Hg. White et al \[[@R05]\] also reported that treatment with azilsartan at 40 mg for 6 weeks reduced systolic BP by 15 mm Hg. Regarding the effect of combination therapy of an ARB/CCB or an ARB/HCT, Shimosawa et al \[[@R18]\] reported that treatment with candesartan at 8 mg/amlodipine at 5 mg for 16 weeks reduced systolic BP by 20 mm Hg. McInnes et al \[[@R19]\] reported that treatment with candesartan at 8 mg/HCT at 12.5 mg for 26 weeks reduced systolic BP by 16.2 mm Hg in patients with grade I to II essential hypertension. These studies suggest that azilsartan at 40 mg has a capability of reducing BP similar to that of combination therapy of an ARB/CCB or an ARB/HCT. Although the present study did not prove the hypothesis that azilsartan at 40 mg is more efficacious than these combination therapies, the substantial BP-lowering effect of azilsartan at 40 mg was appreciated.

An increase in adverse events during this short-term trial was not observed. Laboratory findings did not suggest any clinically relevant changes in renal function or serum mineral homeostasis secondary to azilsartan. In addition, several studies have shown a powerful BP-lowering effect and high safety of azilsartan when used with a CCB or a diuretic in patients with hypertension. According to the 2017 American College of Cardiology/American Heart Association guidelines, the prevalence of hypertension among adults in the United States was 45.6%, and 53.4% of patients taking antihypertensive medication had BP above the treatment goal \[[@R20]\]. This finding indicates that half of the population with hypertension remains at risk for cardiovascular events. Because the efficacy and tolerability of antihypertensive drug therapy play an important role in control of hypertension, azilsartan could lead to enhanced BP control in patients with hypertension.

Limitations {#s4a}
-----------

This study had several limitations. First, it was an open-labeled, single-arm trial and may thus have potentially biased results. Additionally, the sample size was small. Therefore, a larger trial is required to verify our conclusion. Second, the planned sample size was not achieved, and the study may have been underpowered. However, considering the small difference in BP between baseline and 24 weeks, it would be difficult to achieve statistical significance even if the enrollment was completed. This may mitigate the influence of the lower-powered statistical test on the conclusion of the study.

Conclusions {#s4b}
-----------

Azilsartan at 40 mg did not result in a greater decrease in BP than a fixed-dose combination tablet of an ARB/CCB or an ARB/HCT. However, our findings suggest a substantial BP-lowering effect of azilsartan at 40 mg, which could lead to a reduction in the number of patients with BP above the treatment goal.
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